Scandinavian ChemoTech's subsidiary sums up a very successful participation at ESVONC
In addition to a very successful veterinary congress for Vetiqure AB, a poster was also published where our TSE treatment of a horse showed an outstanding result.
After a successful congress, in which many of Europe's leading veterinarians in oncology participated, we can announce that our TSE™ technology and vetIQure™ created a lot of attention.
We would like to thank the organisers of ESVONC and the veterinarians from Evidensia and AniCura who actively helped us make connections within their respective organisations.
A special thank you goes to veterinarian Majbritt M.E Larsen, Specialist in small animal internal medicine and head of Oncology at Evidensia Specialistdjursjukhuset Helsingborg, for our collaboration which, among other things, has resulted in the poster that was published at the congress.
Link to the press release where the poster is also published
“It has been an intense weekend in Italy where we met the market for the first time and where the old static electroporation was also exhibited. It feels like our analysis of the market and the potential for TSE in veterinary medicine has been completely correct. The interest in a less destructive method that is gentler and that reduces the risks of necrosis and inflammation is very big. It is now important that we continue our focus and create both commercial and clinical success from all the expressions of interest we received.” - says Mohan Frick, CEO of ChemoTech
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
